DelveInsight’s, “Alopecia Areata Pipeline Insight 2023” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Alopecia Areata pipeline landscape. It covers the Alopecia Areata pipeline drug profiles, including Alopecia Areata clinical trials and nonclinical stage products. It also covers the Alopecia Areata therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the Alopecia Areata Pipeline treatment landscape of the report, click here @ Alopecia Areata Pipeline Outlook
Key Takeaways from the Alopecia Areata Pipeline Report
- DelveInsight’s Alopecia Areata Pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Alopecia Areata.
- The leading Alopecia Areata Companies include Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma, and others
- Promising Alopecia Areata Pipeline Therapies include 5% Minoxidil Topical Foam, Dutasteride, CTP-543, 8 mg BID, SHR0302, Jaktinib, Baricitinib, and others
- The US FDA has granted BTD and Fast Track Designation (FTD) to CTP-543 for the treatment of alopecia areata. Recently, the company has presented the positive results from two Phase III studies (THRIVE-AA1, THRIVE-AA2) at the 31st European Academy of Dermatology and Venereology (EADV) Congress. Furthermore, the company intends to submit the NDA and the data fromthe THRIVE-AA1 study to the US FDA by the first half of 2023.
- PF-06651600 (Pfizer) is the first in a new investigational class of covalent kinase inhibitors that have high selectivity for Janus kinase 3 (JAK3) and members of the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family. Ritlecitinib has been shown to block the activity of signaling molecules and immune cells believed to contribute to loss of hair in people with alopecia areata. Ritlecitinib has been granted Breakthrough Therapy designation from the US FDA for the treatment of alopecia areata in September 2018. Currently, PF-06651600 is in registration phase for the treatment of alopecia areata.
- LH-8 (Legacy Healthcare SA) is an investigational topical drug. Among the actives present in Coacillium, various flavonoids, polyphenols and methylxanthines have been associated, enabling a pleiotropic mechanism (i.e., multiple targets), to simultaneously reverse immunoinflammatory reactions and their deleterious consequences on hair follicles and adjacent dermal tissues. Currently it is in Phase II/III, doubleblind, vehicle-controlled, randomized, multi-center trial, evaluating the efficacy and safety of Coacillium cutaneous solution in children and adolescents with moderate (25% to 50% baldness) to severe (>50%baldness) alopecia areata.
For further information, refer to the detailed Alopecia Areata Unmet Needs, Alopecia Areata Market Drivers, and Alopecia Areata Market Barriers, click here for Alopecia Areata Ongoing Clinical Trial Analysis
Alopecia Areata Overview
Alopecia areata (AA) is a form of alopecia that impacts hair follicles, nails, and rarely, the retinal pigment epithelium. It typically presents with round patches and is a type of non-scarring hair loss. A significant feature of the hair follicle is its relative immune privilege, this mainly established by suppression of surface molecules required for presenting auto antigens to CD8+ T lymphocytes (i.e., MHC class I) and by the generation of an inhibitory local signaling environment. The breakdown of the immune privilege of the hair follicle has been thought to be a significant driver of AA.
Alopecia Areata Emerging Drugs Profile
- Deuruxolitinib: Concert Pharmaceuticals
Concert Pharmaceuticals is developing deuruxolitinib (CTP-543), an oral inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted CTP-543 breakthrough therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata. The company is evaluating the efficacy and safety of deuruxolitinib in adult patients with moderate to severe alopecia areata in its THRIVE-AA Phase III clinical program. Concert reported positive topline data from the clinical trials. Data from the clinical trials are intended to form the basis of a New Drug Application (NDA) planned to be submitted to the US Food and Drug Administration (FDA) by the first half of 2023.
- EQ101: Equillium
EQ101 is a first-in-class, tri-specific inhibitor of IL-2, IL-9 and IL-15, three inflammatory cytokines implicated in multiple diseases. EQ101 was also shown to be well tolerated with a favorable safety profile with no drug-related SAEs and no dose-limiting toxicities. The drug is currently formulated for intravenous administration, with subcutaneous formulation development underway. It is currently in the Phase II stage of its development in alopecia areata, a dermatological autoimmune disorder.
- MAX 40070: Maxinovel Pharmaceuticals
MAX-40070 is a topical JAK/Tyk2 inhibitor developed by Maxinovel. Preclinical studies have shown that topical administration of MAX-40070 could achieve an effective exposure in skin tissue while maintaining low systemic exposure. MAX-40070 has the potential to minimize the systemic side effects of oral JAK inhibitors and eventually demonstrates its high benefit/risk ratio through clinical trials, which may ultimately provide robust evidence to support its more broadly use in treating dermatological autoimmune disorders. Currently, the drug is in Phase I stage of its development for the treatment of Alopecia Areata.
Request a sample and discover the recent advances in Alopecia Areata Ongoing Clinical Trial Analysis and Medications, click here @ Alopecia Areata Treatment Landscape
Alopecia Areata Pipeline Therapeutics Assessment
There are approx. 18+ Alopecia Areata companies which are developing the Alopecia Areata therapies. The Alopecia Areata companies which have their Alopecia Areata drug candidates in the most advanced stage, i.e. phase III include, Concert Pharmaceuticals.
Dive deep into rich insights for drugs for Alopecia Areata Market Drivers and Alopecia Areata Market Barriers, click here @ Alopecia Areata Unmet Needs and Analyst Views
Scope of the Alopecia Areata Pipeline Report
- Coverage- Global
- Alopecia Areata Companies- Concert Pharmaceuticals, Equillium, Maxinovel Pharmaceuticals, TechnoDerma Medicines, Sichuan Kelun-Biotech Biopharmaceutical, Pfizer, Reistone Biopharma, and others
- Alopecia Areata Pipeline Therapies- 5% Minoxidil Topical Foam, Dutasteride, CTP-543, 8 mg BID, SHR0302, Jaktinib, Baricitinib, and others.
- Alopecia Areata Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Alopecia Areata Mergers and acquisitions, Alopecia Areata Licensing Activities @ Alopecia Areata Emerging Drugs, and Recent Trends
Table of Content
- Introduction
- Executive Summary
- Alopecia Areata: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Alopecia Areata– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Deuruxolitinib: Concert Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid-Stage Products (Phase II)
- EQ101: Equillium
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- MAX 40070: Maxinovel Pharmaceuticals
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Alopecia Areata Key Companies
- Alopecia Areata Key Products
- Alopecia Areata- Unmet Needs
- Alopecia Areata- Market Drivers and Barriers
- Alopecia Areata- Future Perspectives and Conclusion
- Alopecia Areata Analyst Views
- Alopecia Areata Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services